Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4460-4469

  Feldmann, Georg ^a,b   Mishra, Anjali ^a   Hong, Seung Mo ^a   Bisht, Savita ^a   Strock, Christopher J ^a   Ball, Douglas W ^a   Goggins, Michael ^a   Maitra, Anirban ^a   Nelkin, Barry D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; RAL PROTEIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE 5; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RAL GTP-BINDING PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953149881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1107     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin 2008;58:71-96.
2. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol 2001;2:749-759
3. Tsai LH, Delalle I, Caviness VS, Jr., Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994;371:419-423
4. Lew J, Huang QQ, Qi Z, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 1994;371:423-426
5. Ohshima T, Ward JM, Huh CG, et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 1996;93:11173-11178
6. Noble W, Olm V, Takata K, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38:555-565
7. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004;1697:137-142
8. Thiery JP, Boyer B, Tucker G, Gavrilovic J, Valles AM. Adhesion mechanisms in embryogenesis and in cancer invasion and metastasis. Ciba Found Symp 1988;141:48-74.
9. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007;7:246-255
10. Rosales JL, Lee KY. Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 2006;28:1023-1034
11. Strock CJ, Park JI, Nakakura EK, et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006;66:7509-7515
12. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533-545
13. Lim KH, O'Hayer K, Adam SJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006;16:2385-2394
14. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806
15. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554
16. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-7782
17. Calhoun ES, Hucl T, Gallmeier E, et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res 2006;66:7920-7928
18. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM. Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 2005;85:1003-1012
19. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-2196
20. Fendrich V, Waldmann J, Esni F, et al. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr Relat Cancer 2007;14:865-874
21. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-1133
22. Feldmann G, Fendrich V, McGovern K, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008;7:2725-2735
23. Mullendore ME, Koorstra JB, Li YM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009;15:2291-2301
24. Bisht S, Feldmann G, Koorstra JB, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008;7:3878-3888
25. Nikolic M, Dudek H, Kwon YT, Ramos YF, Tsai LH. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 1996;10:816-825 (Pubitemid 26114738)
26. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-2057
27. Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF->MEK->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 2005;65:4870-4880
28. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 2004;24:10868-10881
29. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157-188
30. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-3816
31. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-247
32. Hirano T, Shino Y, Saito T, et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 2002;21:5923-5928
33. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-1438
34. Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 2007;11:673-694
35. Falsetti SC, Wang DA, Peng H, et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol 2007;27:8003-8014
36. Wan Y, Hur W, Cho CY, et al. Synthesis and target identification of hymenialdisine analogs. Chem Biol 2004;11:247-259
37. Rzasa RM, Kaller MR, Liu G, et al. Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorganic Med Chem 2007;15:6574-6595
38. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004;10:452-458
39. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev 2007;6:464-479
40. Emkey R, Freedman S, Feig LA. Characterization of a GTPase-activating protein for the Ras-related Ral protein. J Biol Chem 1991;266:9703-9706 (Pubitemid 21906713)
41. Bhullar RP, Seneviratne HD. Characterization of human platelet GTPase activating protein for the Ral GTP-binding protein. Biochim Biophys Acta 1996;1311:181-188
42. Shirakawa R, Fukai S, Kawato M, et al. Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases. J Biol Chem 2009;284:21580-21588
43. Tian X, Rusanescu G, Hou W, Schaffhausen B, Feig LA. PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism. EMBO J 2002;21:1327-1338
44. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007;29:356-370
45. Kesavapany S, Amin N, Zheng YL, et al. p35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates Rac-dependent Extracellular Signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule-associated protein 1b distribution in neurons. J Neurosci 2004;24:4421-4431
46. Yang HS, Hinds PW. Phosphorylation of ezrin by cyclin-dependent kinase 5 induces the release of Rho GDP dissociation inhibitor to inhibit Rac1 activity in senescent cells. Cancer Res 2006;66:2708-2715
47. Gillardon F, Steinlein P, Burger E, Hildebrandt T, Gerner C. Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor. Proteomics 2005;5:1299-1307